Glaucoma is the most common cause of irreversible vision loss in the
world. The only proven method to treat the disease by reduction of
intraocular pressure (IOP). IOP act as a modifiable risk factor in
glaucoma. Liposomes have been considered as one of the effective
pharmaceutical therapies in reducing IOP in glaucoma and receive
widespread attention in research due to their special characteristics.
Recent studies such as liposomal Latanoprost are still in failure
clinical trials. This review focus on the therapeutic application of
liposomal in the neuro-ocular brain. The routes of drug administration
for the treatment of glaucoma are topical, systemic, periocular and
intravitreal. The treatment of glaucoma using drug-carrier liposome
shows less invasive and more effective when applied topically since it
contains bilayer vesicles which can breach the corneal barrier. To
conclude, using the nanocarrier for the topical administration technique
is better compared to normal drug application as it is more effective
and less invasive.